Using a new imaging technique to improve bladder cancer diagnosis and treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the feasibility of a newly designed optical coherence tomography (OCT) catheter for capturing images of bladder tumors and the normal bladder wall during transurethral resection of bladder tumors (TURBT). By utilizing OCT, the study seeks to provide a non-invasive 'optical biopsy' method that could potentially reduce the need for repeat TURBT procedures and improve the grading and staging of bladder cancer. Participants will undergo imaging with the OCT device during their TURBT procedure, which may lead to better treatment options and reduced healthcare costs for bladder cancer patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> 18 years.
* Have at least 1 suspected bladder tumour seen at cystoscopy.
* Have a bladder that is accessible for cystoscopy.
* Be in a physical condition to undergo a TURBT.
* Eligible patients must be fully informed about the study and written signed informed consent must be obtained prior to any study related investigation/intervention.

Exclusion Criteria:

* Pregnant or lactating women.
* The only tumour site is at the bladder neck.
* The tumour(s) is larger than 2 centimetres in diameter.
* \>5 tumours present.
* Solely a suspected flat lesion present.

Where it's running

• Amsterdam University Medical Center
  Amsterdam, Netherlands Recruiting
• Amsterdam University Medical Center
  Amsterdam, North Holland, Netherlands Not yet recruiting

Study contacts

• Study coordinator: Marinka Remmelink, MD
• Email: m.j.remmelink@amsterdamumc.nl
• Phone: +310204441376

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion

  This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.

  Recruiting at 10 sites Phase 3 Merck Sharp & Dohme LLC · Kaohsiung City and 9 other locations · NCT07829783

• Personalized 3D Tumoroids from Your Tumor to Test Treatments

  Researchers are using patient tumor tissue and blood to grow personalized 3D, vascularized tumoroids with autologous immune cells to help tailor treatments for kidney, bladder, and prostate cancers.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07820566

• Irreversible Electroporation for Recurrent Pelvic Tumors

  This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT07782164

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.